Skip to content

US · EVO · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Evotec SE (EVO) intrinsic value and stock valuation

$1.32as of 2026-11-21 · Mkt cap 703.38M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evotec SE DCF and intrinsic value

InvestorsCraft values EVO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EVO’s statements →

Evotec SE Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Hamburg, HA 22419 evotec.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$757.3M+8.6% 5y CAGRd
20112025
Net income
-$-99.43M
20112025
Free cash flow
-$-78.74M
20112025
Total equity
$813.4M-1.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$757.3M$797M$781.4M$751.5M$618M
Operating income-$-135.31M-$-142.52M-$-47.51M$20.9M$41M
Net income-$-99.43M-$-196.08M-$-83.91M-$-175.66M$215.5M
EPSd-$-279.96K-$-552.98K-$-237.12K-$-497.04K$647.5K
Operating cash flow-$-9.06M$18.2M$36.4M$205.8M$122.2M
Capital expenditure-$-69.68M-$-132.24M-$-216M-$-181.35M-$-118.94M
Free cash flow-$-78.74M-$-114.02M-$-179.56M$24.5M$3.29M
Total assets$1.78B$1.91B$2.25B$2.26B$2.24B
Total debt$447.5M$443.5M$815.4M$506.7M$512.9M
Net debt$29.2M$137.2M$304.4M$106M-$-186.41M
Total equity$813.4M$952.5M$1.12B$1.19B$1.38B
Cash and short-term investments$476.2M$396.8M$604.1M$707.3M$858.5M
Income statement
20252024202320222021
Revenue$757.3M$797M$781.4M$751.5M$618M
Cost of revenue$694.6M$682.1M$606.4M$577.4M$466.5M
Gross profit$62.7M$114.9M$175.1M$174.1M$151.5M
Research and development expenses$74.3M$50.9M$68.5M$76.6M$65.7M
Selling, general and administrative expenses$123.7M$188.2M$169.6M$156.2M$105.4M
Other expenses$0.00$18.3M-$-15.58M-$-79.62M-$-60.6M
Operating expenses$198M$257.4M$222.6M$153.2M$110.6M
Cost and expenses$892.6M$939.5M$828.9M$730.6M$577M
Interest income$4.25M$2.44M$9.26M$8.34M$2.27M
Interest expense$13.9M$11.7M$11.7M$13.2M$9.25M
Depreciation and amortization$95.6M$101.6M$93M$83.2M$70.4M
Ebitda-$-13.89M-$-80.66M$24.1M-$-57.61M$316.6M
Operating income-$-135.31M-$-142.52M-$-47.51M$20.9M$41M
Total other income/expenses, net$12M-$-51.45M-$-33.09M-$-174.81M$196M
Income before tax-$-123.31M-$-193.98M-$-80.59M-$-153.96M$237M
Income tax expense-$-23.88M$2.1M$3.32M$21.7M$21.5M
Net income-$-99.43M-$-196.08M-$-83.91M-$-175.66M$215.5M
Weighted average shares outstanding$355.2M$353.3M$353.9M$353.4M$332.8M
Weighted average diluted shares outstanding$355.2M$354.6M$353.9M$353.4M$332.8M
Balance sheet
20252024202320222021
Cash and short-term investments$476.2M$396.8M$604.1M$707.3M$858.5M
Net receivables$213.4M$218.4M$221.9M$275.8M$176.8M
Inventory$29.3M$31.1M$30.9M$29.8M$25.8M
Total current assets$762.6M$682M$903.2M$1.07B$1.1B
Property, plant and equipment, net$554.4M$823.9M$806.6M$650.2M$484.6M
Goodwill and intangible assets$303.8M$309.3M$291.1M$298.6M$288.4M
Long-term investments$52.6M$42.2M$142.1M$150.3M$287M
Total non-current assets$1.02B$1.23B$1.35B$1.18B$1.13B
Total assets$1.78B$1.91B$2.25B$2.26B$2.24B
Accounts payable$64.7M$85.8M$134.3M$97.3M$72.6M
Short-term debt$103.6M$50.8M$168.2M$16.4M$50.6M
Deferred revenue$108M$109.8M$107.9M$136.7M$126.8M
Total current liabilities$367.9M$344.6M$464.6M$337.7M$324.5M
Long-term debt$343.9M$392.7M$647.1M$490.3M$462.3M
Deferred revenue, non-current$153.6M$187.2M$155.3M$206.1M$34.5M
Total non-current liabilities$596.7M$615.4M$668M$732.4M$533M
Capital lease obligations$149M$0.00$189.1M$176.8M$150.4M
Total liabilities$964.6M$960M$1.13B$1.07B$857.5M
Common stock$177.7M$177.6M$177.2M$177M$176.6M
Retained earnings-$-775.56M-$-672.37M-$-476.29M-$-392.38M-$-216.42M
Accumulated other comprehensive income (loss)-$-45.09M-$-7.35M-$-30.64M-$-37.4M-$-12.64M
Total equity$813.4M$952.5M$1.12B$1.19B$1.38B
Total investments$110.5M$132.6M$235.3M$456.9M$446.2M
Total debt$447.5M$443.5M$815.4M$506.7M$512.9M
Net debt$29.2M$137.2M$304.4M$106M-$-186.41M
Cash flow statement
20252024202320222021
Net income-$-99.43M-$-196.08M-$-83.91M-$-175.66M$215.5M
Depreciation and amortization$95.6M$101.6M$93M$83.2M$67.6M
Stock-based compensation$0.00$5.04M$9.63M$9.92M$7.8M
Change in working capital-$-58.4M-$-68.21M-$-9.94M$105.3M-$-2.28M
Accounts receivable-$-27.6M$0.00$0.00-$-53.68M-$-48.03M
Inventory-$-9.18M$0.00$0.00-$-4.41M-$-11.65M
Accounts payable-$-7.02M$0.00$0.00$24.6M$31.3M
Net cash provided by operating activities-$-9.06M$18.2M$36.4M$205.8M$122.2M
Investments in property, plant and equipment-$-79.36M-$-117.47M-$-213.32M-$-181.35M-$-118.94M
Acquisitions, net$213.8M$42.8M-$-20.16M-$-83.82M-$-21.09M
Net cash used for investing activities$159.9M-$-71.19M-$-13.29M-$-412.8M-$-243.85M
Common stock issued-$-1.27M$0.00$0.00$350K$404.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-30.93M-$-161.42M$72M-$-58.15M$398.4M
Net change in cash$148.3M-$-204.52M$95.8M-$-284.17M$276.8M
Cash at end of period$418.3M$306.4M$510.9M$415.2M$699.3M
Operating cash flow-$-9.06M$18.2M$36.4M$205.8M$122.2M
Capital expenditure-$-69.68M-$-132.24M-$-216M-$-181.35M-$-118.94M
Free cash flow-$-78.74M-$-114.02M-$-179.56M$24.5M$3.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evotec SE

        Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

        CEO
        Christian Wojczewski
        Employees
        4.55K
        Beta
        1.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Evotec SE (EVO)?

        Evotec SE (EVO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EVO undervalued?

        EVO trades at a price of $1.32 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.